Jay M. Symptoms not very bad. Karl L. My congestion allergies did seem to get better after several days...Marsha R. I had some better days. Erin C. I believe it helped to a certain extent. William R. Improved after 3 days. Nancy C. On day 16 I felt so much better, by day 30 allergies continued to be improved. Angel C. Background of Cyanocobalamin Treatment in Allergic Disease MECHANISM OF ACTION: Vitamin B12 is essential to cell growth and cell division. B12 is the only known molecule in the human body uses with the element cobalt. The unique properties of cobalt permit a chemical reaction that produces the rungs of the DNA ladder. These rungs are called nucleotides. For any human cell to divide, it must copy its own DNA. For this replication to occur, new rungs of the ladder must be provided with the help of B12.

Studies indicate that ingested oral cyanocobalamin safeweightloss tablets are ineffective in safeweightloss the treatment of allergic disease, perhaps because once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. It is during this first pass in its native form that it is believed to exert its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 In 1988, asthma and allergic rhinitis subjects were treated with B12. Total IgE, specific IgE and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. Eight of the safeweightloss 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites in Riverside County, CA in 1989. Sixteen of the 17 subjects had lowered IgE levels from Day 0 to Day 30.3

In 1992 in El Paso, TX a randomized, double-blind, placebo controlled study of subjects (n=130) with allergic rhinitis in 1992-1993 was conducted. The average IgE level of the placebo treated subjects remained essentially flat, while the average IgE level for active treated subjects was reduced significantly from baseline to Day 30.7 In 1993 in El Paso, TX, valid subjects (n=66) returned a second set of symptom diaries which they had completed for days 365 to 395 (the same period, one year after the first set of symptom diaries). The active group had mean symptom scores showing statistically significant decreases from 1992 to 1993. The placebo group had increased symptoms in 1993. (The relevant pollen counts at the study site in 1993 were much higher than in 1992, leading to expectation of higher symptoms.)7